S1GE34 Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
Notes are coming soon
Seagen Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$34.86|
|52 Week High||US$48.36|
|52 Week Low||US$27.38|
|1 Month Change||0%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-40.69%|
Recent News & Updates
|S1GE34||BR Biotechs||BR Market|
Return vs Industry: Insufficient data to determine how S1GE34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how S1GE34 performed against the BR Market.
|S1GE34 Average Weekly Movement||n/a|
|Biotechs Industry Average Movement||9.7%|
|Market Average Movement||6.5%|
|10% most volatile stocks in BR Market||10.4%|
|10% least volatile stocks in BR Market||3.1%|
Stable Share Price: Insufficient data to determine S1GE34's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine S1GE34's volatility change over the past year.
About the Company
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
|S1GE34 fundamental statistics|
Is S1GE34 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|S1GE34 income statement (TTM)|
|Cost of Revenue||US$1.68b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 15, 2023
|Earnings per share (EPS)||-3.43|
|Net Profit Margin||-34.16%|
How did S1GE34 perform over the long term?See historical performance and comparison